​

Funding Round

Series B - ESCAPE Bio

Series B - ESCAPE Bio

Investment Firm

Overview

ESCAPE Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases.

Announced Date

Sep 14, 2020

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Wellington Management

Wellington Management

Wellington Management is a debt and early_stage_venture and late_stage_venture and private_equity and venture firm.

Participant Investors

10

Investor Name
Participant InvestorNovartis Venture Fund
Participant InvestorNovo Holdings
Participant InvestorOUP (Osage University Partners)
Participant InvestorWellington Management
Participant InvestorSutter Hill Ventures

Round Details and Background

ESCAPE Bio raised $73000000 on 2020-09-14 in Series B

ESCAPE Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Aug 19, 2015
Venture Round - ESCAPE Bio
-20.0M
Jul 16, 2019
Venture Round - ESCAPE Bio
-31.1M
Sep 14, 2020
Series B - ESCAPE Bio
13-73.0M
Jul 12, 2017
Series A - ESCAPE Bio
6-63.0M

Recent Activity

There is no recent news or activity for this profile.